Pfizer axes a key Duchenne MD program after PhII flop, raising new doubts for a drug category that attracted Roche and Biogen
Pfizer is jettisoning another disappointing drug that’s been in the clinic for Duchenne muscular dystrophy. The pharma giant says it’s axing work on domagrozumab (PF-06252616) — raising the odds against one R&D focus in the field that has attracted some marquee players around the world.
The drug is one of several designed to inhibit myostatin, which flopped against a one-year test of muscle strength, failing to help patients to any significant degree. By suppressing myostatin, which blunts muscles, the theory is that a proper therapy can help slow the muscle-wasting ailment that inevitably proves fatal to the boys who inherit this disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.